tirzepatide vs retatrutide 10mg — What the Research Shows Retatrutide 10 mg: vial guide

Maass, F

Research shows that people with Graves disease are more likely to be deficient in vitamin D than the general population

Consequently, the applicability of these findings to patients with SID and SIH remains limited

Disclaimer Educational content only

Your journey is unique, and our ongoing support reflects that commitment to your personalized care

The exception: in March 2024, the FDA approved a supplemental indication for semaglutide 2.4 mg (Wegovy) to reduce the risk of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke in adults with established cardiovascular disease and either obesity or overweight (SELECT trial, Lincoff et al., New England Journal of Medicine 2023)